Mr Joao Pedro Ferreira

  • Affiliate (Institute of Cardiovascular & Medical Sciences)

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019
Number of items: 18.

2021

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Raafs, A. et al. (2021) Identification of sex‐specific biomarkers predicting new‐onset heart failure. ESC Heart Failure, 8(5), pp. 3512-3520. (doi: 10.1002/ehf2.13476) (PMID:34156155) (PMCID:PMC8497379)

Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2021) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, (doi: 10.1002/ejhf.2350) (PMID:34536265) (Early Online Publication)

Ferreira, J. P. et al. (2021) Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 117(10), pp. 2228-2236. (doi: 10.1093/cvr/cvaa279) (PMID:33002110)

Verdonschot, J. A.J. et al. (2021) Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 20, 163. (doi: 10.1186/s12933-021-01357-9)

Ferreira, J. P., Cleland, J. G. , Lam, C. S.P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., LaPolice, D. A., Greenberg, B. and Zannad, F. (2021) New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, (doi: 10.1007/s00392-021-01891-2) (PMID:34128083) (Early Online Publication)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)

Ferreira, J. P., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., La Police, D. A., Cleland, J. G.F. , Greenberg, B. and Zannad, F. (2021) Plasma D‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial. European Journal of Heart Failure, 23(4), pp. 648-656. (doi: 10.1002/ejhf.2003) (PMID:32959502)

Ferreira, J. P. et al. (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC: Heart Failure, 9(4), pp. 268-277. (doi: 10.1016/j.jchf.2020.11.010) (PMID:33549556)

Ferreira, J. P. et al. (2021) Impact of geographic region on the COMMANDER-HF Trial. JACC: Heart Failure, 9(3), pp. 201-211. (doi: 10.1016/j.jchf.2020.11.007) (PMID:33549557)

2020

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

2019

Mehra, M. R. et al. (2019) A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 40(44), pp. 3593-3602. (doi: 10.1093/eurheartj/ehz427) (PMID:31461239) (PMCID:PMC6868495)

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi: 10.1161/CIRCHEARTFAILURE.118.005897) (PMID:31104495)

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)

This list was generated on Tue Dec 7 08:25:23 2021 GMT.
Jump to: Articles
Number of items: 18.

Articles

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Raafs, A. et al. (2021) Identification of sex‐specific biomarkers predicting new‐onset heart failure. ESC Heart Failure, 8(5), pp. 3512-3520. (doi: 10.1002/ehf2.13476) (PMID:34156155) (PMCID:PMC8497379)

Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2021) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, (doi: 10.1002/ejhf.2350) (PMID:34536265) (Early Online Publication)

Ferreira, J. P. et al. (2021) Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 117(10), pp. 2228-2236. (doi: 10.1093/cvr/cvaa279) (PMID:33002110)

Verdonschot, J. A.J. et al. (2021) Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 20, 163. (doi: 10.1186/s12933-021-01357-9)

Ferreira, J. P., Cleland, J. G. , Lam, C. S.P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., LaPolice, D. A., Greenberg, B. and Zannad, F. (2021) New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, (doi: 10.1007/s00392-021-01891-2) (PMID:34128083) (Early Online Publication)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)

Ferreira, J. P., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., La Police, D. A., Cleland, J. G.F. , Greenberg, B. and Zannad, F. (2021) Plasma D‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial. European Journal of Heart Failure, 23(4), pp. 648-656. (doi: 10.1002/ejhf.2003) (PMID:32959502)

Ferreira, J. P. et al. (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC: Heart Failure, 9(4), pp. 268-277. (doi: 10.1016/j.jchf.2020.11.010) (PMID:33549556)

Ferreira, J. P. et al. (2021) Impact of geographic region on the COMMANDER-HF Trial. JACC: Heart Failure, 9(3), pp. 201-211. (doi: 10.1016/j.jchf.2020.11.007) (PMID:33549557)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

Mehra, M. R. et al. (2019) A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 40(44), pp. 3593-3602. (doi: 10.1093/eurheartj/ehz427) (PMID:31461239) (PMCID:PMC6868495)

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi: 10.1161/CIRCHEARTFAILURE.118.005897) (PMID:31104495)

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)

This list was generated on Tue Dec 7 08:25:23 2021 GMT.